One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients: A randomized, controlled trial

OBJECTIVE: Traditional blood glucose–lowering agents do not sustain adequate glycemic control in most type 2 diabetic patients. Preclinical studies with exenatide have suggested sustained improvements in β-cell function. We investigated the effects of 52 weeks of treatment with exenatide or insulin...

Descripción completa

Detalles Bibliográficos
Autores principales: Bunck, Mathijs C., Diamant, Michaela, Cornér, Anja, Eliasson, Bjorn, Malloy, Jaret L., Shaginian, Rimma M., Deng, Wei, Kendall, David M., Taskinen, Marja-Riitta, Smith, Ulf, Yki-Järvinen, Hannele, Heine, Robert J.
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2009
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2671094/
https://www.ncbi.nlm.nih.gov/pubmed/19196887
http://dx.doi.org/10.2337/dc08-1797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2671094/
https://www.ncbi.nlm.nih.gov/pubmed/19196887
http://dx.doi.org/10.2337/dc08-1797

Ejemplares similares